MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an
alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R)
is being evaluated in patients with unresectable and metastatic melanoma.